Woodline Partners’s Opus Genetics IRD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.2M Sell
661,729
-772,984
-54% -$3.21M 0.01% 813
2026
Q2
$5.9M Buy
1,434,713
+80,683
+6% +$376K 0.02% 650
2026
Q1
$6.16M Buy
+1,354,030
New +$4.68M 0.02% 619

Other funds holding IRD

Woodline Partners's IRD Position: Q3 2026 in Review

Woodline Partners reduced its Opus Genetics (IRD) stake by 54% in Q3 2026, selling an estimated $3.21M and leaving 661,729 shares worth $3.2M. The position accounts for 0.01% of the portfolio, ranked #813.

Woodline Partners first reported a position in IRD in Q1 2026 and has held it in 3 quarters since. The position peaked at $6.16M in Q1 2026. 112 funds tracked by Wall St. Rank hold IRD as of Q3 2026.

  • Woodline Partners held 661,729 shares of Opus Genetics worth $3.2M as of Q3 2026.
  • Woodline Partners sold 772,984 Opus Genetics shares in Q3 2026, an estimated $3.21M.
  • Opus Genetics made up 0.01% of Woodline Partners's portfolio in Q3 2026, its #813 holding.
  • Woodline Partners first reported a position in Opus Genetics in Q1 2026 and has held it in 3 quarters since.
  • Woodline Partners's Opus Genetics position peaked at $6.16M in Q1 2026.
  • 112 funds tracked by Wall St. Rank held Opus Genetics as of Q3 2026.

Based on Woodline Partners's 13F filing for Q3 2026, filed 16 Nov 2026.